Yam, Clinton
Esteva, Francisco J.
Patel, Miral M.
Raghavendra, Akshara S.
Ueno, Naoto T.
Moulder, Stacy L.
Hess, Kenneth R.
Shroff, Girish S.
Hodge, Silvia
Koenig, Kimberly H.
Chavez Mac Gregor, Mariana
Griner, Robin L.
Yeung, Sai-Ching J.
Hortobagyi, Gabriel N.
Valero, Vicente
Funding for this research was provided by:
Susan G. Komen for the Cure (KG081048, KG081048, KG081048)
Article History
Received: 19 October 2018
Accepted: 12 November 2018
First Online: 5 January 2019
Compliance with ethical standards
:
: FJE has received honoraria from Novartis and Pfizer for consultancy. MCM has received honoraria for serving on the advisory boards of Roche and Pfizer and has received institutional research funding from Novartis. SCJY has received research funding and grant support from Bristol-Myers Squibb and DepoMed. GNH was the principal investigator of the BOLERO-2 trial and received research funding from Norvatis for conducting the trial and honoraria for chairing the protocol steering committee. VV has received honoraria from Novartis for consultancy. All other authors declare no relevant potential conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
: Informed consent was obtained from all individual participants included in the study.